Landos Biopharma, Inc (LABP)

Etorro trading 970x250

About Landos Biopharma, Inc

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia. Address: 1800 Kraft Drive, Blacksburg, VA, United States, 24060

Landos Biopharma, Inc News and around…

Latest news about Landos Biopharma, Inc (LABP) common stock and company :

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
18 May, 2022 FinancialContent

Gainers Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 17.3% to $0.4 during Wednesday's pre-market session. ...

7 Hot Upcoming IPOs to Watch For in 2022
17 May, 2022 FinancialContent

There were a record 1,035 IPOs on the U.S. stock market in 2021. Of these, 159 have returned profits to investors. This means that ...

56 Stocks Moving In Friday's Mid-Day Session
13 May, 2022 FinancialContent

Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies ...

The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma
13 May, 2022 Yahoo! Finance

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog

23 Stocks Moving in Friday's Pre-Market Session
13 May, 2022 FinancialContent

Gainers OTR Acquisition Corp. (NASDAQ: OTRA) rose 88.7% to $18.21 in pre-market trading after filing on Thursday showed ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
13 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're starting off the final day of the workweek with an overview of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
12 May, 2022 Yahoo! Finance

On Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase 2b Trial of Omilancor Later this Year NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the first quarter ended March

12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 May, 2022 FinancialContent

Gainers Allena Pharma (NASDAQ:ALNA) stock increased by 94.9% to $0.15 during Thursday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
12 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the start of another day comes our breakdown of the biggest pre-market stock movers and this time it's for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
11 May, 2022 Yahoo! Finance

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

We're Keeping An Eye On Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate
08 May, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2022
12 Apr, 2022 FinancialContent

Upgrades TD Securities upgraded the previous rating for Louisiana-Pacific Corp (NYSE:LPX) from Hold to Buy. In the fourth quarter, ...

How Is The Market Feeling About Landos Biopharma Inc. - Common Stock?
28 Mar, 2022 FinancialContent

Landos Biopharma Inc. - Common Stock's (NASDAQ:LABP) short percent of float has risen 22.22% since its last report. The company recently ...

Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
24 Mar, 2022 Yahoo! Finance

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of NX-13 in Ulcerative Colitis and Phase 1a Trial of LABP-104 in Normal Healthy Volunteers; Top Line Results for Both Studies Expected in Mid-2022 BLACKSBURG, Va., March 24, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medic

Landos Biopharma Appoints Roger Adsett to its Board of Directors
10 Mar, 2022 Yahoo! Finance

BLACKSBURG, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it has appointed Roger Adsett to the Company’s Board of Directors, effective March 8, 2022. Mr. Adsett will serve on the Audit Committee of the Board. With the addition of Mr. Adsett, the Landos Board has been expanded to six members. Mr. Adsett is a healthcare industry ve

12 Health Care Stocks Moving In Tuesday's After-Market Session
08 Mar, 2022 FinancialContent

Gainers FIGS (NYSE:FIGS) stock rose 11.1% to $15.6 during Tuesday's after-market session. Today's trading volume for this security ...

60 Biggest Movers From Yesterday
10 Feb, 2022 FinancialContent

Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
09 Feb, 2022 FinancialContent

Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's ...

Component Price Targets Imply 40% Gains Ahead For Russell 2000
08 Feb, 2022 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Stocks That Hit 52-Week Lows On Monday
07 Feb, 2022 FinancialContent

On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in ...

Stocks That Hit 52-Week Lows On Friday
04 Feb, 2022 FinancialContent

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta ...

What Percentage Of Landos Biopharma, Inc. (NASDAQ:LABP) Shares Do Insiders Own?
04 Feb, 2022 Yahoo! Finance

Every investor in Landos Biopharma, Inc. ( NASDAQ:LABP ) should be aware of the most powerful shareholder groups...

Oversold Conditions For Landos Biopharma (LABP)
05 Jan, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

What 4 Analyst Ratings Have To Say About Landos Biopharma
03 Jan, 2022 FinancialContent

Over the past 3 months, 4 analysts have published their opinion on Landos Biopharma (NASDAQ:LABP) stock. These analysts are typically ...

Look Under The Hood: VTI Has 12% Upside
22 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $265.55 per unit.

Here's Why We're Not At All Concerned With Landos Biopharma's (NASDAQ:LABP) Cash Burn Situation
17 Nov, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

80 Biggest Movers From Yesterday
17 Nov, 2021 FinancialContent

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a ...

53 Stocks Moving In Tuesday's Mid-Day Session
16 Nov, 2021 FinancialContent

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 ...

Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021
16 Nov, 2021 FinancialContent

Upgrades According to Maxim Group, the prior rating for VirTra Inc (NASDAQ:VTSI) was changed from Hold to Buy. For the ...

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
15 Nov, 2021 Yahoo! Finance

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn’s Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conferenc

Landos Biopharma, Inc (LABP) is a NASDAQ Common Stock listed in , ,

970x250